

Carlos Cruchaga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526934/publications.pdf>

Version: 2024-02-01

305
papers

38,081
citations

7672

79
h-index

4305

179
g-index

389
all docs

389
docs citations

389
times ranked

37022
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	9.4	2,697
3	<i>TREM2</i> Variants in Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2013, 368, 117-127.	13.9	2,385
4	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
5	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
6	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 436-441.	9.4	1,676
7	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nature Genetics</i> , 2018, 50, 524-537.	9.4	1,124
8	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	6.0	1,085
9	Human apoE Isoforms Differentially Regulate Brain Amyloid- β Peptide Clearance. <i>Science Translational Medicine</i> , 2011, 3, 89ra57.	5.8	924
10	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. <i>Nature</i> , 2017, 549, 523-527.	13.7	852
11	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
12	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
13	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , 2014, 505, 550-554.	13.7	425
14	Alzheimer's Disease Genetics: From the Bench to the Clinic. <i>Neuron</i> , 2014, 83, 11-26.	3.8	396
15	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015, 138, 3673-3684.	3.7	359
16	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
17	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	1.1	347
18	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. <i>Neuron</i> , 2013, 78, 256-268.	3.8	344

#	ARTICLE	IF	CITATIONS
19	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. <i>Nature Neuroscience</i> , 2017, 20, 1052-1061.	7.1	330
20	Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. <i>Nature Genetics</i> , 2012, 44, 1349-1354.	9.4	303
21	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
22	Expression of Novel Alzheimer's Disease Risk Genes in Control and Alzheimer's Disease Brains. <i>PLoS ONE</i> , 2012, 7, e50976.	1.1	278
23	Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families. <i>PLoS ONE</i> , 2012, 7, e31039.	1.1	270
24	Coding variants in TREM2 increase risk for Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 5838-5846.	1.4	263
25	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. <i>Acta Neuropathologica</i> , 2016, 131, 925-933.	3.9	262
26	A statistical framework for cross-tissue transcriptome-wide association analysis. <i>Nature Genetics</i> , 2019, 51, 568-576.	9.4	262
27	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	4.1	260
28	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid- β^2 pathology. <i>Molecular Neurodegeneration</i> , 2019, 14, 1.	4.4	253
29	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. <i>Nature Communications</i> , 2020, 11, 667.	5.8	246
30	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. <i>Nature Neuroscience</i> , 2019, 22, 1903-1912.	7.1	242
31	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 264.	4.5	227
32	TREM2 Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 449.	4.5	221
33	Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. <i>Lancet Neurology</i> , The, 2016, 15, 174-184.	4.9	217
34	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , 2017, 133, 839-856.	3.9	199
35	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. <i>Human Molecular Genetics</i> , 2012, 21, 3500-3512.	1.4	198
36	Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. <i>Molecular Psychiatry</i> , 2009, 14, 501-510.	4.1	196

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. <i>Human Molecular Genetics</i> , 2012, 21, 4558-4571.	1.4	196
38	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	192
39	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. <i>Molecular Psychiatry</i> , 2020, 25, 1859-1875.	4.1	191
40	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. <i>Acta Neuropathologica</i> , 2020, 140, 513-534.	3.9	186
41	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
42	Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. <i>Human Molecular Genetics</i> , 2009, 18, 3125-3135.	1.4	180
43	Meningeal lymphatics affect microglia responses and anti-A β immunotherapy. <i>Nature</i> , 2021, 593, 255-260.	13.7	179
44	TREM2 and Neurodegenerative Disease. <i>New England Journal of Medicine</i> , 2013, 369, 1564-1570.	13.9	174
45	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	1.5	174
46	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
47	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
48	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	4.5	166
49	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.4	166
50	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155
51	Alzheimer's Therapeutics Targeting Amyloid Beta 1-42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. <i>PLoS ONE</i> , 2014, 9, e111899.	1.1	151
52	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 691.	4.5	151
53	Association of TMEM106B Gene Polymorphism With Age at Onset in Granulin Mutation Carriers and Plasma Granulin Protein Levels. <i>Archives of Neurology</i> , 2011, 68, 581-6.	4.9	148
54	Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. <i>ELife</i> , 2016, 5, .	2.8	145

#	ARTICLE	IF	CITATIONS
55	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. <i>Neurology</i> , 2012, 79, 221-228.	1.5	144
56	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	4.5	144
57	TARDBP 3' UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , 2009, 118, 633-645.	3.9	139
58	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 71.	3.0	131
59	TREM2 is associated with the risk of Alzheimer's disease in Spanish population. <i>Neurobiology of Aging</i> , 2013, 34, 1711.e15-1711.e17.	1.5	130
60	TREM2 is associated with increased risk for Alzheimer's disease in African Americans. <i>Molecular Neurodegeneration</i> , 2015, 10, 19.	4.4	130
61	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. <i>Nature Medicine</i> , 2014, 20, 1452-1457.	15.2	116
62	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. <i>PLoS Genetics</i> , 2010, 6, e1001101.	1.5	111
63	Rare variants in FBN1 and FBN2 are associated with severe adolescent idiopathic scoliosis. <i>Human Molecular Genetics</i> , 2014, 23, 5271-5282.	1.4	111
64	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. <i>Nature Medicine</i> , 2019, 25, 152-164.	15.2	111
65	Missense variant in TREML2 protects against Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1510.e19-1510.e26.	1.5	110
66	Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. <i>PLoS Genetics</i> , 2014, 10, e1004758.	1.5	109
67	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. <i>Alzheimer's and Dementia</i> , 2018, 14, 205-214.	0.4	109
68	Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. <i>Neurobiology of Aging</i> , 2016, 37, 209.e1-209.e7.	1.5	106
69	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. <i>Nature Neuroscience</i> , 2021, 24, 1302-1312.	7.1	105
70	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 34.	3.0	103
71	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	102
72	Exome-Sequencing Confirms DNAJC5 Mutations as Cause of Adult Neuronal Ceroid-Lipofuscinosis. <i>PLoS ONE</i> , 2011, 6, e26741.	1.1	101

#	ARTICLE	IF	CITATIONS
73	The epigenetic landscape of Alzheimer's disease. <i>Nature Neuroscience</i> , 2014, 17, 1138-1140.	7.1	101
74	A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease. <i>Science Translational Medicine</i> , 2016, 8, 341ra76.	5.8	100
75	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ϵ 4 genotype. <i>Brain</i> , 2018, 141, 1828-1839.	3.7	99
76	<i>Chi3l1</i> /YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	98
77	Association and Expression Analyses With Single-Nucleotide Polymorphisms in <i>TOMM40</i> in Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1013.	4.9	97
78	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
79	Genetic variants and functional pathways associated with resilience to Alzheimer's disease. <i>Brain</i> , 2020, 143, 2561-2575.	3.7	93
80	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 736.	4.5	92
81	Genome-wide analyses as part of the international FTL-D-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTL. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
82	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	3.9	87
83	Variation in <i>MAPT</i> is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8050-8054.	3.3	84
84	TREM2 and neurodegenerative disease. <i>New England Journal of Medicine</i> , 2013, 369, 1567-8.	13.9	81
85	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. <i>Journal of Neurochemistry</i> , 2010, 112, 1305-1315.	2.1	76
86	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001713.	3.9	75
87	Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. <i>EMBO Molecular Medicine</i> , 2020, 12, e12308.	3.3	73
88	Phosphorylated Tau- $\text{A}\beta$ 242 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer's Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2014, 75, 723-731.	0.7	72
89	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.4	72
90	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	4.9	72

#	ARTICLE	IF	CITATIONS
91	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	3.7	70
92	Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 29.	4.4	70
93	Polygenic risk and hazard scores for Alzheimer's disease prediction. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 456-465.	1.7	70
94	TYROBP genetic variants in early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 48, 222.e9-222.e15.	1.5	69
95	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. <i>Genome Medicine</i> , 2017, 9, 100.	3.6	67
96	Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). <i>Translational Psychiatry</i> , 2013, 3, e256-e256.	2.4	66
97	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	3.7	66
98	A polygenic burden of rare variants across extracellular matrix genes among individuals with adolescent idiopathic scoliosis. <i>Human Molecular Genetics</i> , 2016, 25, 202-209.	1.4	65
99	Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019, 142, 2581-2589.	3.7	65
100	Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e15918.	1.1	64
101	CSF progranulin increases in the course of Alzheimer's disease and is associated with TREM2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	64
102	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. <i>Genome Medicine</i> , 2018, 10, 43.	3.6	62
103	Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. <i>Acta Neuropathologica</i> , 2017, 133, 955-966.	3.9	60
104	Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 603-612.	1.2	59
105	Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2013, 34, 2234.e13-2234.e19.	1.5	59
106	Polygenic risk scores in familial Alzheimer disease. <i>Neurology</i> , 2017, 88, 1180-1186.	1.5	59
107	A missense variant in SLC39A8 is associated with severe idiopathic scoliosis. <i>Nature Communications</i> , 2018, 9, 4171.	5.8	59
108	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. <i>Molecular Neurodegeneration</i> , 2019, 14, 18.	4.4	58

#	ARTICLE	IF	CITATIONS
109	Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. <i>JAMA Network Open</i> , 2019, 2, e191350.	2.8	58
110	Palmitoylation-induced Aggregation of Cysteine-string Protein Mutants That Cause Neuronal Ceroid Lipofuscinosis. <i>Journal of Biological Chemistry</i> , 2012, 287, 37330-37339.	1.6	57
111	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	2.8	56
112	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE- ϵ 4 Carriers. <i>PLoS Genetics</i> , 2013, 9, e1003685.	1.5	55
113	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. <i>BMC Neurology</i> , 2017, 17, 198.	0.8	55
114	The Role of Variation at A β PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 377-387.	1.2	53
115	The TMEM106B FTD-protective variant, rs1990621, is also associated with increased neuronal proportion. <i>Acta Neuropathologica</i> , 2020, 139, 45-61.	3.9	51
116	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 1231.	4.5	49
117	Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. <i>Circulation Research</i> , 2019, 124, 114-120.	2.0	49
118	Characterizing the Role of Brain Derived Neurotrophic Factor Genetic Variation in Alzheimer's Disease Neurodegeneration. <i>PLoS ONE</i> , 2013, 8, e76001.	1.1	48
119	Cortical Atrophy and Language Network Reorganization Associated with a Novel Progranulin Mutation. <i>Cerebral Cortex</i> , 2009, 19, 1751-1760.	1.6	47
120	Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 955-959.	1.1	47
121	Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTD and PSP. <i>Translational Psychiatry</i> , 2018, 8, 265.	2.4	47
122	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321.	4.1	47
123	SUCLG2 identified as both a determinant of CSF A β 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	1.4	45
124	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 745-756.	1.2	45
125	Parkinson disease is not associated with C9ORF72 repeat expansions. <i>Neurobiology of Aging</i> , 2013, 34, 1519.e1-1519.e2.	1.5	44
126	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. <i>Neurobiology of Aging</i> , 2016, 37, 208.e1-208.e9.	1.5	44

#	ARTICLE	IF	CITATIONS
127	A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1037-1054.	1.2	44
128	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	5.8	43
129	Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 833-42.	1.2	43
130	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. <i>Annals of Neurology</i> , 2021, 89, 254-265.	2.8	42
131	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
132	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101767.	1.4	41
133	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. <i>PLoS Genetics</i> , 2017, 13, e1007045.	1.5	40
134	Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. <i>Neurobiology of Aging</i> , 2014, 35, 2681-2690.	1.5	39
135	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
136	Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants. <i>PLoS ONE</i> , 2017, 12, e0185777.	1.1	38
137	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	1.5	37
138	Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. <i>Alzheimer's and Dementia</i> , 2021, 17, 1474-1486.	0.4	37
139	Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. <i>Alzheimer's and Dementia</i> , 2014, 10, 366-371.	0.4	36
140	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , 2019, 75, 42-50.	1.5	36
141	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. <i>Stroke</i> , 2021, 52, 132-141.	1.0	36
142	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. <i>Neurology</i> , 2020, 95, e3104-e3116.	1.5	35
143	Influence of Coding Variability in APP- β Metabolism Genes in Sporadic Alzheimer's Disease. <i>PLoS ONE</i> , 2016, 11, e0150079.	1.1	34
144	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	4.9	34

#	ARTICLE	IF	CITATIONS
145	Alzheimer's disease: rare variants with large effect sizes. <i>Current Opinion in Genetics and Development</i> , 2015, 33, 49-55.	1.5	33
146	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2011, 32, 547.e11-547.e16.	1.5	32
147	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. <i>Neurobiology of Aging</i> , 2018, 66, 179.e17-179.e29.	1.5	32
148	Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by <i>APOE</i> Genotype. <i>JAMA Neurology</i> , 2019, 76, 1099.	4.5	32
149	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	2.1	31
150	Identification of rare variants in Alzheimer's disease. <i>Frontiers in Genetics</i> , 2014, 5, 369.	1.1	30
151	Discovery and validation of autosomal dominant Alzheimer's disease mutations. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 67.	3.0	29
152	Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkers. <i>Neurology</i> , 2019, 93, e1605-e1617.	1.5	29
153	Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3'-Azido-3'-deoxythymidine (AZT)-resistant Polymerase to AZT-5'-triphosphate. <i>Journal of Biological Chemistry</i> , 2003, 278, 42710-42716.	1.6	28
154	Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. <i>Alzheimer's and Dementia</i> , 2020, 16, 1134-1145.	0.4	28
155	The association of genetic variants in interleukin-1 genes with cognition: Findings from the cardiovascular health study. <i>Experimental Gerontology</i> , 2011, 46, 1010-1019.	1.2	27
156	The influence of genetic variants in <i>SORL1</i> gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
157	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 587-598.	1.5	27
158	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
159	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , 2021, 7, e571.	0.9	27
160	Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review. <i>Journal of Stroke</i> , 2019, 21, 276-289.	1.4	27
161	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. <i>NeuroImage</i> , 2022, 256, 119228.	2.1	27
162	Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke. <i>Stroke</i> , 2020, 51, 2454-2463.	1.0	26

#	ARTICLE	IF	CITATIONS
163	Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. <i>Brain</i> , 2022, 145, 2541-2554.	3.7	26
164	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. <i>Scientific Reports</i> , 2016, 6, .	1.6	25
165	Effect of <i>BDNF</i> Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	2.8	25
166	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
167	Neuronal VCP loss of function recapitulates FTLTDP pathology. <i>Cell Reports</i> , 2021, 36, 109399.	2.9	25
168	5'-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. <i>Neurobiology of Disease</i> , 2009, 33, 164-170.	2.1	24
169	TMEM106B: a strong FTLTDP disease modifier. <i>Acta Neuropathologica</i> , 2014, 127, 419-422.	3.9	24
170	Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in European-Americans. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 73.	3.0	24
171	Inhibition of Phosphorolysis Catalyzed by HIV-1 Reverse Transcriptase Is Responsible for the Synergy Found in Combinations of 3'-Azido-3'-deoxythymidine with Nonnucleoside Inhibitors. <i>Biochemistry</i> , 2005, 44, 3535-3546.	1.2	23
172	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218111.	1.1	23
173	Higher Body Mass Index Is Associated with Lower Cortical Amyloid- β Burden in Cognitively Normal Individuals in Late-Life. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 817-827.	1.2	23
174	Overlapping genetic architecture between Parkinson disease and melanoma. <i>Acta Neuropathologica</i> , 2020, 139, 347-364.	3.9	23
175	Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 1-17.	0.7	22
176	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 69.	3.0	22
177	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 825-837.	0.8	22
178	Selective Excision of Chain-terminating Nucleotides by HIV-1 Reverse Transcriptase with Phosphonoformate as Substrate. <i>Journal of Biological Chemistry</i> , 2006, 281, 27744-27752.	1.6	21
179	Identification of plexin A4 as a novel clusterin receptor links two Alzheimer's disease risk genes. <i>Human Molecular Genetics</i> , 2016, 25, 3467-3475.	1.4	21
180	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 209.	1.4	21

#	ARTICLE	IF	CITATIONS
181	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 230.	1.4	21
182	SORL1 variants across Alzheimer's disease European American cohorts. <i>European Journal of Human Genetics</i> , 2016, 24, 1828-1830.	1.4	20
183	Plasma amyloid β^2 levels are driven by genetic variants near <i>APOE, BACE1, APP, PSEN2</i> : A genome-wide association study in over 12,000 non-demented participants. <i>Alzheimer's and Dementia</i> , 2021, 17, 1663-1674.	0.4	20
184	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
185	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1958.e1-1958.e2.	1.5	19
186	Cell specific peripheral immune responses predict survival in critical COVID-19 patients. <i>Nature Communications</i> , 2022, 13, 882.	5.8	19
187	Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 86.	3.0	18
188	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1469-1482.	1.2	18
189	Causal Effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 Levels on Ischemic Stroke. <i>Stroke</i> , 2021, 52, e316-e320.	1.0	18
190	Clinically early-stage CSP \pm mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. <i>Acta Neuropathologica Communications</i> , 2015, 3, 73.	2.4	17
191	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 1125.	4.5	17
192	Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. <i>Stroke</i> , 2019, 50, 1339-1345.	1.0	17
193	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	11.7	17
194	Rare and de novo coding variants in chromodomain genes in Chiari I malformation. <i>American Journal of Human Genetics</i> , 2021, 108, 100-114.	2.6	17
195	Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke. <i>Science Translational Medicine</i> , 2022, 14, eabk0135.	5.8	17
196	The Dystonia Coalition: A Multicenter Network for Clinical and Translational Studies. <i>Frontiers in Neurology</i> , 2021, 12, 660909.	1.1	16
197	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.5	16
198	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	16

#	ARTICLE	IF	CITATIONS
199	Remote cognitive assessment approaches in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, e038144.	0.4	15
200	Comparing amyloid- β^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	3.9	15
201	Association of <i>BDNF</i> Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	4.5	15
202	Multi-ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke. <i>Brain</i> , 2022, 145, 2394-2406.	3.7	15
203	Genetic high throughput screening in Retinitis Pigmentosa based on high resolution melting (HRM) analysis. <i>Experimental Eye Research</i> , 2013, 116, 386-394.	1.2	14
204	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	1.2	14
205	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 212-219.	0.6	14
206	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. <i>Stroke</i> , 2019, 50, 3618-3621.	1.0	13
207	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.4	13
208	Chitinase-3-like 1 protein (<i>CHI3L1</i>) locus influences cerebrospinal fluid levels of YKL-40. <i>BMC Neurology</i> , 2016, 16, 217.	0.8	12
209	An <i>APOE</i> -independent cis -eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2018, 66, 178.e1-178.e8.	1.5	12
210	Exome sequencing revealed <i>PDE11A</i> as a novel candidate gene for early-onset Alzheimer's disease. <i>Human Molecular Genetics</i> , 2021, 30, 811-822.	1.4	12
211	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.4	12
212	Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1331-1349.	1.9	12
213	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. <i>JAMA Network Open</i> , 2019, 2, e1913491.	2.8	11
214	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	1.5	11
215	Exome-wide rare variant analysis in familial essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 109-116.	1.1	11
216	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, 29.	2.4	11

#	ARTICLE	IF	CITATIONS
217	Genetic Discoveries in AD Using CSF Amyloid and Tau. <i>Current Genetic Medicine Reports</i> , 2014, 2, 23-29.	1.9	10
218	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. <i>Neurology</i> , 2019, 93, e851-e863.	1.5	10
219	Single nucleotide variations in <i>ZBTB46</i> are associated with post-thrombolytic parenchymal haematoma. <i>Brain</i> , 2021, 144, 2416-2426.	3.7	10
220	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
221	TMEM230 in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 212.e1-212.e3.	1.5	9
222	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. <i>Scientific Reports</i> , 2019, 9, 10854.	1.6	9
223	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12038.	1.2	9
224	Advances in Genetic and Molecular Understanding of Alzheimer's Disease. <i>Genes</i> , 2021, 12, 1247.	1.0	9
225	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. <i>Neurobiology of Aging</i> , 2021, 109, 43-51.	1.5	9
226	Murine roseolovirus does not accelerate amyloid- β^2 pathology and human roseoloviruses are not over-represented in Alzheimer disease brains. <i>Molecular Neurodegeneration</i> , 2022, 17, 10.	4.4	9
227	The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. <i>Alzheimer's and Dementia</i> , 2022, 18, 1889-1897.	0.4	9
228	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of <i>Klotho</i> heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	1.1	9
229	Cruchaga & Goate reply. <i>Nature</i> , 2015, 520, E5-E6.	13.7	8
230	CpG-related SNPs in the MS4A region have a dose-dependent effect on risk of late-onset Alzheimer disease. <i>Aging Cell</i> , 2019, 18, e12964.	3.0	8
231	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 196.	2.4	8
232	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021, 32, 849-860.	1.8	8
233	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.5	8
234	CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. <i>Experimental Gerontology</i> , 2017, 90, 83-89.	1.2	7

#	ARTICLE	IF	CITATIONS
235	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTL cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.5	7
236	Network dysfunction in cognitively normal APOE ϵ 4 carriers is related to subclinical tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 116-126.	0.4	7
237	Cognitively normal APOE ϵ 4 carriers have specific elevation of CSF SNAP-25. <i>Neurobiology of Aging</i> , 2021, 102, 64-72.	1.5	7
238	Novel progranulin variants do not disrupt progranulin secretion and cleavage. <i>Neurobiology of Aging</i> , 2013, 34, 2538-2540.	1.5	6
239	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke/subtitle. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1165-1771.	1.8	6
240	Paving the road for the study of epigenetics in neurodegenerative diseases. <i>Acta Neuropathologica</i> , 2016, 132, 483-485.	3.9	6
241	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. <i>Neurobiology of Aging</i> , 2018, 70, 325.e1-325.e5.	1.5	6
242	Long runs of homozygosity are associated with Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 142.	2.4	6
243	RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3137.	1.0	6
244	A Multi-center Genome-wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021, 36, 2795-2801.	2.2	5
245	01-04-03: COMPARING SMARTPHONE-ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P224.	0.4	4
246	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
247	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e041129.	0.4	4
248	A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer. <i>Biochemical Journal</i> , 2007, 405, 165-171.	1.7	3
249	Cruchaga & Goate reply. <i>Nature</i> , 2015, 520, E10-E10.	13.7	3
250	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016, 1303, 299-314.	0.4	3
251	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.4	3
252	Lack of evidence supporting a role for DPP6 sequence variants in Alzheimer's disease in the European American population. <i>Acta Neuropathologica</i> , 2021, 141, 623-624.	3.9	3

#	ARTICLE	IF	CITATIONS
253	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2021, 151, 105247.	2.1	3
254	Gantenerumab inâ€depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.4	2
255	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.4	2
256	O4-01-01: Association of genetic variants with cerebrospinal fluid protein levels of ACE, MMP3 and other proteins and risk for Alzheimer's disease. , 2013, 9, P677-P678.		1
257	P1-045: EXOME ARRAY ANALYSIS IDENTIFIES NOVEL RISK VARIANTS FOR ALZHEIMER'S DISEASE WITH ONSET BEFORE 65 YEARS. , 2014, 10, P319-P319.		1
258	P1-055: Exome-sequencing in a large dataset of late-onset families with Alzheimer's disease. , 2015, 11, P359-P359.		1
259	Protective genetic variants in the MS4A gene cluster modulate microglial activity. <i>Alzheimer's and Dementia</i> , 2020, 16, e039431.	0.4	1
260	Alzheimer's Disease Alters Oligodendrocytic Glycolytic and Ketolytic Gene Expression. <i>FASEB Journal</i> , 2021, 35, .	0.2	1
261	F2-01-03: A rare coding variant in PLD3 confers high risk for Alzheimer's disease. , 2013, 9, P312-P312.		0
262	O2-12-04: ALZHEIMER'S DISEASE RISK VARIANTS IN PHOSPHOLIPASE D3 ALTER APP METABOLISM BY GAMMA-DEPENDENT AND GAMMA-INDEPENDENT MECHANISMS. , 2014, 10, P192-P192.		0
263	O1-04-02: EXOME-SEQUENCING IN LATE-ONSET FAMILIES IDENTIFIED ADDITIONAL CANDIDATES GENES FOR ALZHEIMER'S DISEASE. , 2014, 10, P135-P135.		0
264	O1-04-05: NOVEL CODING VARIANTS IN TREM2 INCREASE RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P136-P136.		0
265	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
266	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
267	P1-221: Dynamic Relationships Between â€œBig Fiveâ€ Personality Traits, Alzheimerâ€™s Disease Biomarkers, and Cognition in Autosomal Dominant Alzheimerâ€™s Disease. , 2016, 12, P491-P492.		0
268	F1â€01â€02: Alzheimer's Disease Sequencing Project: Search for Alzheimer's Disease Resilience Genes That May Modify Disease Susceptibility in Specific Apoe Genotype Backgrounds. <i>Alzheimer's and Dementia</i> , 2016, 12, P162.	0.4	0
269	P3â€097: <i>SORL1</i> Variants Across Alzheimerâ€™s Disease Cohorts in European Americans. <i>Alzheimer's and Dementia</i> , 2016, 12, P857.	0.4	0
270	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P252.	0.4	0

#	ARTICLE	IF	CITATIONS
271	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
272	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.4	0
273	[P3â€“094]: RESOURCE OF MULTIPLEX AFRICAN AMERICAN FAMILIES FOR WHOLEâ€GENOME SEQUENCING. Alzheimer's and Dementia, 2017, 13, P970.	0.4	0
274	[P3â€“257]: DECODING VARIABILITY IN AGEâ€ATâ€ONSET BETWEEN PARENTS AND CHILDREN WITH SPORADIC ALZHEIMER DISEASE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1041.	0.4	0
275	[ICâ€Pâ€061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.4	0
276	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.4	0
277	[P2â€“345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.4	0
278	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.4	0
279	[O2â€“08â€“05]: NOVEL CANDIDATE VARIANTS IN LOAD DETECTED BY THE FAMILIAL ALZHEIMER SEQUENCING (FASE) PROJECT. Alzheimer's and Dementia, 2017, 13, P572.	0.4	0
280	[O2â€“18â€“02]: PHOSPHOLIPASE D3 CONTRIBUTES TO ALZHEIMER'S DISEASE RISK VIA DISRUPTION OF AÎ² CLEARANCE THROUGH THE LYSOSOME. Alzheimer's and Dementia, 2017, 13, P602.	0.4	0
281	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
282	P1â€“173: BRAIN TRANSCRIPTOMICS STUDY REVEALS DIFFERENTIAL EXPRESSION OF THE THREE <i>TREM2</i> TRANSCRIPT IN AD AND <i>TREM2</i> MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P345.	0.4	0
283	P3â€494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES. Alzheimer's and Dementia, 2018, 14, P1311.	0.4	0
284	P2â€105: NOMINATION OF NOVEL CANDIDATE GENES FOR FAMILIAL LATE ONSET ALZHEIMER DISEASE AFTER EVALUATION OF GENEâ€BASED FAMILYâ€BASED METHODS. Alzheimer's and Dementia, 2018, 14, P709.	0.4	0
285	O4â€01â€04: CIRCULAR RNAS IN ALZHEIMER'S DISEASE BRAIN TISSUES. Alzheimer's and Dementia, 2018, 14, P1401.	0.4	0
286	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
287	S1-02-01: REVIEW OF GWAS GENES AND POLYGENIC RISK SCORES. , 2018, 14, P198-P198.		0
288	P2â€295: QUANTIFYING THE CONTRIBUTIONS OF HERITABLE AND NONâ€HERITABLE FACTORS TO AGEâ€ATâ€ONSET OF ALZHEIMER DEMENTIA IN ADULT CHILDREN OF AFFECTED PARENTS. Alzheimer's and Dementia, 2018, 14, P794.	0.4	0

#	ARTICLE	IF	CITATIONS
289	O5â€04â€03: IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES AND POTENTIALLY NOVEL DRUGS FOR FRONTOTEMPORAL LOBAR DEMENTIA WITH TAU INCLUSIONS BY A DEPENDABLE ANALYSIS APPROACH. Alzheimer's and Dementia, 2018, 14, P1651.	0.4	0
290	P4â€487: BRAIN SOMATIC MOSAICISM IN 17Q21.31 <i>MAPT</i> H1â€ASSOCIATED ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1499.	0.4	0
291	ICâ€Pâ€023: EARLY RESTINGâ€STATE NETWORK DYSFUNCTION IN <i>APOE</i> Î¼4 CARRIERS WITHOUT BIOMARKER EVIDENCE OF ALZHEIMER'S DISEASE IS RELATED TO SUBCLINICAL TAU CHANGES. Alzheimer's and Dementia, 2019, 15, P30.	0.4	0
292	Global system segregation enhances reserve in normal aging and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037930.	0.4	0
293	Lateâ€onset Alzheimer's diseaseâ€associated gene, CPAMD8 , increases Bâ€CTF and affects APP processing through regulation of the autophagyâ€lysosome pathway. Alzheimer's and Dementia, 2020, 16, e040559.	0.4	0
294	Alzheimerâ€™associated circular RNA circHOMER1 regulates synaptic gene expression and cognition. Alzheimer's and Dementia, 2020, 16, e042335.	0.4	0
295	Orderings of biomarker changes for Alzheimer disease in cognitively normal individuals from 18 to 101 years of age. Alzheimer's and Dementia, 2020, 16, e043187.	0.4	0
296	A comprehensive analysis of dementia cerebrospinal fluid biomarkers using GWAs, polygenic risk scores and Mendelian randomization in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043233.	0.4	0
297	Prediction of Alzheimerâ€™s disease using plasma RNA sequences. Alzheimer's and Dementia, 2020, 16, e043273.	0.4	0
298	Proteogenomic analysis of cerebrospinal fluid reveals causal role of proteins from the autophagyâ€lysosome pathway in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043422.	0.4	0
299	Multiomics approaches reveal a link between the MS4A gene loci, TREM2, and microglia function. Alzheimer's and Dementia, 2020, 16, e043592.	0.4	0
300	Identification of blood eQTLs for AD risk loci. Alzheimer's and Dementia, 2020, 16, e043801.	0.4	0
301	Singleâ€nuclei RNAâ€seq of brains carriers of highâ€risk variants and Mendelian mutations. Alzheimer's and Dementia, 2020, 16, e043125.	0.4	0
302	Replication study of ADâ€associated rare variants. Alzheimer's and Dementia, 2022, , .	0.4	0
303	Integrating functional genomics with genetics to understand the biology of ALS and FTD. Med, 2022, 3, 226-227.	2.2	0
304	Using amyloid PET as a biomarker to detect progression of early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
305	Impact of <i>MAPT</i> mutations on transcriptomic signatures of FTD brains and patientâ€derived pluripotent cell models. Alzheimer's and Dementia, 2021, 17, e058313.	0.4	0